Trials in Progress Poster Session: Hepatobiliary, Neuroendocrine/Carcinoid, Pancreatic & other GI Cancer
Hepatobiliary Cancer: Go to 11 Presentations
Neuroendocrine/Carcinoid: Go to 2 Presentations
Pancreatic Cancer: Go to 10 Presentations
- A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
Brian Hemendra Ramnaraign, Steven J. Hughes, Kathryn Hitchcock, et al.
Authors conclusion: Enrollment continues to a maximum of 28 evaluable pts to demonstrate a reduction in historical 30 day postoperative complication rate. NCT03483038
Other GI Cancer: Go to 2 Presentations